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bypass graft. This year, it is half that. Corrected for
inflation, the purchasing power is $900. Similar
changes have affected general thoracic and congenital
heart surgery. 
The increasing number of practicing thoracic sur-
geons and techniques developed by colleagues in other
specialties have increased competition. For example, in
4 years, the number of coronary artery stents increased
from zero to one-half million last year. Could competi-
tion get more intense? You bet it could. Not long ago, an
aorta-coronary bypass graft in a pig was performed with
catheter technology—without incision. Should this
technology prove effective, primary coronary artery
bypass surgery could go the way of surgery for tuber-
culosis. 
Adding to our mounting concerns is the realization
that the esteem in which we are held is eroding.
Evidence of this is the escalating number of malpractice
cases forcing us into more defensive practices. Another
is that the “best and the brightest” are no longer attract-
ed to our specialty. In 1999, of the 16,000 US medical
school graduates, fewer than 100 sought thoracic surgi-
cal residencies. That was not enough to fill the available
positions. 
How could this happen to a specialty that pioneered
heart and lung transplantation, aorta-coronary bypass
surgery, and repair of tetralogy of Fallot in newborn
infants? All of these achievements are now more than
F or thoracic surgeons, this is the best of times and theworst of times. We are in the midst of an unprece-
dented economic boom that has been powered by the
entrepreneurial dreams of millions. It has produced new
products, new services, and a revolution in information
technology. On the horizon looms a revolution in med-
icine through human genomics. 
For thoracic surgeons, results have never been better.
New technologies arrive almost daily to improve
results. In the United States, more than $55 billion is
being invested in medical research. Yet, thoracic sur-
geons are feeling increasingly dejected and under siege.
Accelerating health care costs have resulted in a reallo-
cation of money away from surgical specialties. In
1987, Medicare allocated $4000 for a three-vessel
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15 years old. Somehow our pioneering spirit has been
squelched. There are a number of possible explana-
tions. Perhaps this was as natural and unavoidable as
the “technology S curve.” This concept emanates from
the world of management. In the early stages of a
given technology, such as myocardial revasculariza-
tion, the rate of progress is slow as the advance goes
through the process of winning adherents. This is the
bottom of the S curve. As technology becomes well
understood and widely used, the adoption rate acceler-
ates. This is the middle of the S curve. As technology
matures, improvements are less dramatic. The
technology begins to bump against a growing number
of limitations. This is the top of the S curve. In some
enterprises, the pathfinders manage to overcome these
natural forces of obsolescence. They do it by being
alert to new technologies. They embrace these latest
advances, try new concepts, and launch their enterprise
on a new S curve. Where is coronary surgery on the
first technology S curve? If it is at the top, should we
consider what is necessary to move it to another break-
through, another S curve? The next step could be beat-
ing heart or robotic assisted surgery. 
It is my observation that our excitement with new
technology has been replaced with suspicion. We
have become slow adopters. We were quick to
embrace coronary artery surgery in the early years.
We were slow to adopt the use of the internal thoracic
artery in later years. In 1975, an enormous amount of
data demonstrated the superiority of this graft. We
were slow to change. Thirteen years elapsed. Dr
Floyd Loop’s article in the New England Journal of
Medicine (1986;314:1-6) was the impetus that spurred
cardiologists to demand internal thoracic artery graft-
ing for their patients. Surgeons were pressured into
adopting it. 
Why have thoracic surgeons become slow to adopt
new technology and hesitant to innovate? One possibil-
ity is that we have become victims of our own success.
Procedures have become low risk. Why would we
change? Another possibility is that creative thinking is
not one of our cultivated strengths. Medical schools
require accumulation of a large amount of facts and the
ability to accurately regurgitate this information.
Residents are not encouraged to be creative but rather
to be a younger copy of the best technical and intellec-
tual surgeons. I remember being told and subsequently
repeating to others, “No improvement, please. Today,
we’ll do it my way.”
In addition, the pressure to reduce the costs of health
care in the United States is tremendous. This situation
has produced a paradigm shift. We have gone from
doing everything possible to weighing treatment cost
versus potential benefit. In short, our success, educa-
tion, society’s expectations, and financial pressures
have biased us against innovation. If we are to survive
and prosper, we must cast off these shackles and free
our innovative spirit. In 1862, with the Civil War fully
engaged, Abraham Lincoln challenged Congress. “The
dogmas of the quiet past,” he said, “are inadequate for
the stormy present. The occasion is piled high with dif-
ficulty, and we must rise with the occasion. . . . We
must think anew and act anew.” [December 1, 1862,
message to Congress.]
We must think anew and act anew in clinical
practice
Will thoracic surgery survive when the very opera-
tions we perform are being replaced by less invasive
techniques practiced by other specialties? The answer
is “yes” if we are willing to innovate and change.
Charles Darwin wrote, “It is not the strongest of the
species that survives, nor the most intelligent; it is the
one that is most adaptable to change.”
Our specialty has been and should be one of con-
stant innovation. The first issue of The Journal of
Thoracic Surgery in 1931 had not one reference to
the heart. My, how things have changed. Not only has
journal content changed, but so have the very dis-
eases we treat. In my professional lifetime, rheumat-
ic disease has become infrequent, only to be replaced
by degenerative disease. Tuberculosis has become
rare, replaced by carcinoma of the lung. Surgical pro-
cedures have changed. Mitral valves are now repaired
instead of replaced. Palliative shunts for congenital
heart disease have been replaced by complete repair
in infancy. Yet, there are still huge clinical challenges
and opportunities that require imagination and inno-
vation. Albert Einstein said, “Imagination is more
important than knowledge.” It will take imagination
and innovative surgical solutions to treat the 400,000
new cases of heart failure each year and the uncount-
ed cases of respiratory insufficiency. 
To accomplish this, we need to talk about the thing
we fear the most—change. Historically, surgical thera-
py had been reserved for the most advanced diseases
for which no other therapies were available. Gradually,
these surgical therapies were replaced by medical and
preventive solutions, as they should be. Change has
never been more rapid. If the 1980s were about quality
and the 1990s about reengineering, the 2000s will be
about velocity. Most technology becomes obsolete in 5
to 7 years. Changes in clinical practice must be viewed
as opportunity. We must accelerate our rate of change.
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We must think anew and act anew in education 
In the past quarter century, training of thoracic sur-
geons has changed little in length or format despite an
explosion of knowledge. Standard textbooks have dou-
bled in size and more surgical techniques need to be
learned. Twenty-five years ago, the Norwood proce-
dure, arterial grafting, and volume reduction surgery
did not exist. Yet, we are expected to teach these new
approaches and much more in a 2-year residency pro-
gram. It is impossible to do this well with the best res-
idents and the best teachers. Extending our training
programs to 3 years would fulfill our obligation to our
residents and society. It is time!
Practice patterns have evolved into the subspecialties
of general thoracic, congenital, and acquired heart dis-
ease. It is increasingly rare to find thoracic surgeons
practicing more than one subspecialty. Residents would
benefit from exposure to all three subspecialties to
obtain basic skills and then select one for intensive
training. This approach would provide greater knowl-
edge, experience, and technical expertise. It would
shorten the apprenticeship that most trainees serve after
completion of their residency. Most important, it would
improve patient outcomes.
Postgraduate education has been, at best, haphazard.
This poses a major problem for practitioners because of
the quantity of new information. The total amount of
information available doubles every 21⁄2 years. More
information has been created in the past 40 years than in
the previous 5000. With this proliferation of new knowl-
edge, how is the practitioner to keep up? Fortunately, the
age of global telecommunication is now. Time and dis-
tance have been swept away. New knowledge can be dis-
seminated directly to the practitioner. This very meeting
marks a milestone in postgraduate education. It is the first
major medical meeting to be entirely available over the
Internet and archived for future reference. We have been
joined by 1300 surgeons from 79 countries via the
Internet. Today, we have become a global community of
thoracic surgeons capable of sharing new knowledge
instantaneously.
The Internet brings the potential to deliver didactic
material and surgical techniques to surgeons by the
experts. This would elevate the quality of teaching. Can
you imagine one week having Alain Carpentier explain
the techniques of mitral valve repair and Joel Cooper
discussing volume reduction surgery and the next week
hearing Bruce Lytle discuss arterial revascularization
and Mark Orringer the topic of esophageal resection?
Technologies are available to have these presentations
interactive and archived. The possibilities are stunning
and limited only by our imaginations.
We must think anew and act anew in research 
At no time in human history has the potential been
greater for translating biologic knowledge and techni-
cal capability into powerful tools for preventing and
treating disease. 
Clinical research is the scientific bottleneck through
which all developments flow to patients. Landmark
developments in basic science mean little if clinical
researchers are unable to implement them. The viabili-
ty of clinical research enterprise is in jeopardy. Funding
for clinical research is becoming more difficult.
Today’s cost-conscious health care market has had a
major impact on funding for clinical research. This
impact has been negative.
At the same time, another change has occurred.
Large animal physiologic studies, the traditional model
for thoracic surgical research, have been highly pro-
ductive. This model is perfectly suited to the surgeons’
skills and for their training. Research, however, has
been moving toward the province of molecular biolo-
gists, in which surgical skills are less applicable. There
is certainly no shortage of scientists to perform basic
research. Ninety percent of all scientists who ever lived
are currently alive.
This convergence of change and need provides an
enormous opportunity for surgical scientists. Increased
emphasis on clinical and translational research will
meet an unmet need. Learning the skills of clinical
research and becoming facile with the use of the new
information technology is a huge new opportunity.
Would it not be more practical and productive to pro-
vide residents with these skills rather than basic
research training?
Where is the funding for clinical research in thoracic
surgery? In the United States, the government’s contri-
bution to the total research budget has diminished to
less than 25%. Industry and venture capitalists have
increased their contributions to 75% of the total
research dollars. They have become the de Medicis of
the information age. It is imperative that we forge
mutually beneficial alliances between health care
providers, industries, and venture capitalists.
We must think anew and act anew in health care
delivery 
The health care delivery debate is currently taking
center stage. Pivotal is the realization that our ability to
do good for individuals exceeds society’s current will-
ingness to pay. This simple reality lies behind every
issue in health care today. It is not a comfortable situa-
tion. It is responsible for the dramatic change in atti-
tude toward health care delivery. The time has come to
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face this reality not as a menace, but as an opportunity.
We, as leaders in the medical community, can influence
this process.
Central to the debate about health care delivery is the
question of quality and cost—the two determinants of
value. The cost versus quality contest has always been
lopsided in favor of cost because costs are easily mea-
sured in dollars. Quality is more subjective and much
more difficult to measure.
Today, most proposals concentrate on cost-saving
measures. Some see technology as the enemy because
it raises cost. Adoption of new technology is delayed to
avoid raising cost. Quality is ignored rather than mea-
sured. These are misguided approaches. Our goal
should be to optimize value by simultaneously maxi-
mizing quality and reducing cost.
Eighty years ago, when this organization was found-
ed, the average life expectancy was 54 years. Thoracic
surgeons have contributed to extending life expectancy
to 76 years. The quality of life has surged ahead. This
is a result of the increasing use of services that drive up
the total bill for health care. No one would turn back,
and yet we have failed to emphasize these benefits in
our discussions. We must help turn society’s emphasis
from cost to value.
In industry after industry, it is competition that drives
continuous quality improvement and cost reduction
through innovation. The Food and Drug Administration,
Health Care Financing Administration, and multiple
other agencies have regulated and stifled competition.
Health care reform must reduce these regulations and
build stronger incentives for medical and managerial
innovation. Failure to promote innovation will lower
quality and ration health care. Economist Elizabeth
Teisberg wrote, “Innovation is the only long-term solu-
tion to high-quality, affordable health care.”
Who will drive the innovations necessary to
improve health care delivery? Who better than tho-
racic surgeons? You are natural leaders. You have
risen to the top of the surgical pyramid. You head
complex surgical teams. You are the chairs of depart-
ments and heads of hospitals and major health care
systems. Your leadership extends into the halls of
Congress. A number of you have sharpened your
understanding of the health care delivery system by
attending courses at the Kennedy School of
Government. Through your work and interaction
with multiple teams, you have learned the importance
of collaboration. As Lucianno DeCrescanzo de-
scribes so poignantly, “We are all angels with one
wing: we can only fly while embracing one another.”
This type of collaboration will be necessary across a
wide spectrum of health care and society. 
You understand the techniques and importance of
quantitative measurement of quality. Without this, we
have no ability to measure, evaluate, or improve.
Your creativity and innovativeness have been an
inspiration to the medical world. Finally, you under-
stand most acutely the pains and lessons taught by
failure. You understand that failure is the handmaid-
en of risk and the father of innovation. Innovation
requires people who are willing to take risks and face
failure.
We are those people. So, let’s resolve to renew the
pioneering spirit that was our tradition. Let’s look at
changes in clinical practice as opportunities. Let’s
accelerate our rate of change. Let’s extend our residen-
cy program to 3 years; let’s emphasize and teach clini-
cal and translational research; let’s return to an appre-
ciation of value, not just cost.
And so, let it be said of the first year of a new mil-
lennium, this was the time when thoracic surgeons rec-
ognized the imperative for innovation in clinical prac-
tice, in research, in education, and in health care
delivery. This was the time we had the vision to think
anew and the courage to act anew. 
The world must know, from this hour, from this day,
and from this hall, that thoracic surgeons step forth
with a new sense of purpose, a new sense of possibili-
ty, and a new sense of dedication to the future of our
specialty. I congratulate you on your accomplishments
and wish you Godspeed in the challenges ahead.
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